Drug Profile
Research programme: severe acute respiratory syndrome-coronavirus PL protease inhibitors - Microbial Novoteqs
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Microbial Novoteqs
- Class Antivirals
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Severe acute respiratory syndrome
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Severe acute respiratory syndrome in USA
- 11 Jul 2016 Early research in Severe acute respiratory syndrome in USA (unspecified route)